gary...i don't have WI on my list yet but I have a large flag planted in HDRN...both for patriotic purposes and $$$$$.
Every aspect of what HDRN does...their whole history...is going to thrust the company forward over the next few years. Seriously, where else can you find more of a direct hit than the following release, and that is only 1 subs that is engaged in work for the DOD or DOD clients. i will probably have more on hdrn over the w/e.
(COMTEX) B: Hadron Subsidiary Awarded New $3.6 Million Biodefense Contra
B: Hadron Subsidiary Awarded New $3.6 Million Biodefense Contract By DARPA
ALEXANDRIA, Va., Jul 9, 2001 /PRNewswire via COMTEX/ -- Hadron, Inc. (OTC
Bulletin Board: HDRN) today announced that its Advanced Biosystems, Inc.
subsidiary has been awarded a new $3.6 million contract by the Defense Advanced
Research Projects Agency (DARPA). This eighteen-month contract represents a
continuation of medical biodefense research previously funded by DARPA.
Specifically, this contract funds research into ways to enhance the body's
innate immune response against a wide variety of biological weapons threats. The
areas under investigation will include both in vitro and in vivo investigation
of the effects of certain cytokine combinations, other natural and synthetic
modulators of the innate immune response, computer modeling of cytokines and
cytokine-receptors, and the construction of new peptides which mimic the effects
of certain cytokines. The research is being conducted under the direction of
Advanced Biosystems' President, Dr. Ken Alibek, who has been developing these
and other novel approaches to the development of new prophylactic means and
treatments for a broad spectrum of infectious diseases.
Dr. Alibek stated, "We are gratified by our preliminary research results to
date, and are pleased to continue working with DARPA to advance this research
into new medical concepts regarding protection against biological threat
agents." Hadron's President and Chief Executive Officer, Sterling Phillips,
commented, "We continue to have great confidence in Advanced Biosystems'
multi-phase programs to develop defenses against, and treatments for, biological
agents that may be used in warfare or terrorist attacks. Since support of
national security is the key focus of Hadron, we are pleased these programs are
part of our Company."
Hadron specializes in developing leading edge intelligence and biodefense
solutions in support of our nation's security. Hadron focuses on developing
innovative technical solutions for the intelligence community, analyzing and
supporting defense systems and developing medical defenses and treatments for
toxic agents used in biological warfare and terrorism. The Company's stock
trades on the OTC Electronic Bulletin Board under the symbol HDRN. Hadron can be
found on the Internet at hadron.com . Hadron investor relations can
be contacted at 703-329-9400 or via email at agordon@hadron.com .
Except for the historical information contained herein, this press release
contains forward-looking statements within the meaning of Section 21E of the
Securities and Exchange Act of 1934, as amended, that involve a number of risks
and uncertainties. These forward-looking statements may be identified by
reference to a future period by use of forward-looking terminology such as
"anticipate," "expect," "could," "intend," "may" and other words of similar
nature. There are certain important factors and risks that could cause results
to differ materially from those anticipated by the statements contained herein.
Such factors and risks include business conditions and growth in the information
services, engineering services, software development and government contracting
arenas and in the economy in general. Competitive factors include the pressures
toward consolidation of small government contracts into larger contracts awarded
to major, multi-national corporations; and the Company's ability to continue to
recruit and retain highly skilled technical, managerial and sales/marketing
personnel. Other risks may be detailed from time to time in the Company's
filings with the Securities and Exchange Commission. Hadron undertakes no
obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
SOURCE Hadron, Inc.
CONTACT: Amber Gordon or Sterling Phillips, 703-329-9400, both of
Hadron, Inc.
URL: hadron.com
prnewswire.com
Copyright (C) 2001 PR Newswire. All rights reserved.
-0-
KEYWORD: Virginia
INDUSTRY KEYWORD: CPR
BIO
ARO
SUBJECT CODE: CON
*** end of story *** |
